1209 Triple therapy compared to standard Pegylated interferon alfa 2B + weight based ribavirin for previous nonresponders and relapsers with chronic hepatitis C

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

“…Among 107 references identified, 76 studies were excluded for the following reasons: 23 studies were nonrandomized [16,; 12 studies did not mention ETR or SR [45][46][47][48][49][50][51][52][53][54][55][56]; 20 studies did not compare treatment with and without amantadine but other combinations of treatments including amantadine [18,[57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75]; 2 studies concerned HIV-HCV co-infected patients [76,77]; 2 studies were performed in transplanted patients [78,79]; 1 study did not specify whether patients had received previous therapy or not [80]; 2 did not specify the exact number of patients randomized [81,82]; 14 preliminary studies were excluded as the latest publication of the trial was available [83][84][85][86][87]…”

Treatment of chronic hepatitis C in nonresponders to previous therapy

“…In an ongoing study, Lawitz et al [42] are evaluating the use of triple therapy (PEG-IFN, ribavirin, and amantadine) for previous nonresponders to IFN-based therapy. Participants have been randomly assigned to either PEG-IFN alfa-2b, 1.5 µg/kg/wk, plus ribavirin, 13 mg/kg/d, or the same regimen plus amantadine, 100 mg twice daily.…”